Integra LifeSciences (NASDAQ:IART) Raised to Buy at Wall Street Zen

Integra LifeSciences (NASDAQ:IART) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday, Wall Street Zen reports.

Several other equities research analysts also recently issued reports on IART. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Monday, October 26th. Wells Fargo & Company set a $13.00 price objective on Integra LifeSciences and gave the company an “equal weight” rating in a research note on Thursday, October 22nd. Citizens Jmp dropped their price objective on Integra LifeSciences from $25.00 to $22.00 and set a “market outperform” rating for the company in a research note on Thursday, October 22nd. Zacks Research lowered Integra LifeSciences from a “hold” rating to a “strong sell” rating in a research note on Monday, October 26th. Finally, Truist Financial set a $13.00 price target on Integra LifeSciences and gave the stock a “hold” rating in a research report on Friday, October 23rd. Two research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Reduce” and an average target price of $16.12.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART opened at $12.75 on Friday. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $20.49. The business has a 50-day moving average of $14.83 and a two-hundred day moving average of $14.08. The company has a debt-to-equity ratio of 1.67, a current ratio of 3.62 and a quick ratio of 2.21. The firm has a market capitalization of $991.95 million, a PE ratio of 75.00, a P/E/G ratio of 0.50 and a beta of 1.28.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.03. Integra LifeSciences had a net margin of 0.79% and a return on equity of 18.63%. The business had revenue of $411.18 million during the quarter, compared to the consensus estimate of $413.16 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. As a group, research analysts forecast that Integra LifeSciences will post 2.34 earnings per share for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds have recently modified their holdings of the company. Paradigm Capital Management Inc. NY increased its holdings in Integra LifeSciences by 50.6% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock valued at $37,800,000 after buying an additional 1,347,700 shares during the period. Wellington Management Group LLP raised its stake in Integra LifeSciences by 12.4% in the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after purchasing an additional 160,814 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Integra LifeSciences by 71.4% during the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after purchasing an additional 589,408 shares during the last quarter. Glenmede Trust Co. NA boosted its stake in Integra LifeSciences by 27.4% during the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after acquiring an additional 211,774 shares in the last quarter. Finally, Access Investment Management LLC lifted its position in shares of Integra LifeSciences by 72.0% during the first quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company’s stock valued at $6,034,000 after purchasing an additional 268,085 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.